Skip to main content
. 2013 Jul 31;110(33):13534–13539. doi: 10.1073/pnas.1312911110

Fig. 3.

Fig. 3.

Inhibiting IL-15 signaling reversed the diabetes in IL-15/IL-15Rα double transgenic mice. (A) The blood glucose levels in the double transgenic mice with new onset of diabetes untreated (black, n = 10) or treated with monoclonal anti–IL-2/IL-15Rβ (anti-CD122) antibody TMβ1 for 6 wk (red, n = 12). (B) The blood glucose levels in the IL-15/IL-15Rα transgenic mice with new onset of diabetes untreated (black, n = 10) or treated with the Jak2/3 inhibitor tofacinitib for 4 wk (red, n = 10). (C) Immunohistochemistry staining of F4/80 (macrophage), CD3 (T cells), and B220 (B cells) on the pancreas of mice treated with TMβ1 and the Jak2/3 inhibitor tofacitinb. The data represent five individual mice.